

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 06275-0188001	Application No. 09/367,950
	Applicant Tommy Ekstrom		
	Filing Date August 18, 1999	Group Art Unit 1617	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	5,250,286	10/05/1993	Skupin			
	2	5,795,564	08/18/1998	Aberg et al.			
	3	5,996,576	12/07/2009	Yule			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	4	WO 00/35441	06/22/2000	WIPO				
	5	CA 2123909	06/24/1993	Canada				
	6	CA 2356145	06/24/1993	Canada				
	7	WO 98/31351	07/23/1998	WIPO				
	8	EP 0 523 638	01/20/1993	Europe				
	9	WO 00/53188	09/14/2000	WIPO				
	10	WO 99/00134	01/07/1999	WIPO				
	11	WO 00/30608	06/02/2000	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	12	Response to Notice of Opposition against EP 108577 submitted to EPO, sent by AstraZeneca, dated October 5, 2009 (17 pages)
	13	Rabe et al., "Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomized controlled, double-blind study," The Lancet, Vol. 368, pages 744-753 (2006) and slides based on Rabe et al.
No date!	14	Product insert for Advair Diskus®, Patient's Instructions for Use (3 pages).
no date	15	Product insert for Symbicort® Turbuhaler® (2 pages).
No date	16	Product insert for Pulmicort Turbuhaler® (4 pages).
	17	Barnes, "A Single Inhaler for Asthma?," American Journal of Respiratory and Critical Care Medicine, Vol. 171, pages 95-96 (2005).
	18	O'Bryne et al., "Budesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in Asthma," American Journal of Respiratory and Critical Care Medicine, Vol. 171, pages 129-136 (2005).
	19	Chapter 2, Six-Part Asthma Management Program (International Consensus Report on Diagnosis and Management of Asthma), Allergy, Vol. 47, suppl. 13, pages 6-49 (1992).

Examiner Signature /Jennifer Kim/	Date Considered 03/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 06275-0188001	Application No. 09/367,950
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Tommy Ekstrom	
		Filing Date August 18, 1999	Group Art Unit 1617

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	20	Stephen Wasserman, M.D., "What Is A Rescue Medicine And When Is It Used To Treat Asthma?" ABC News, 2 pages.
	21	Health Facts for You, Asthma Rescue Medicine, University of Wisconsin, March 31, 2008 (2 pages).
	22	Anthony D. D'Urzo, "Inhaled Glucocorticosteroid and Long-Acting β_2 Adrenoceptor Agonist Single-Inhaler Combination for Both Maintenance and Rescue Therapy", Treat. Respir. Med., Vol. 5(6), pages 385-391 (2006).
	23	Kuna et al., "Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations", International Journal of Clinical Practice, Vol. 61(5), pages 725-736 (2007), and slides based on Kuna.
	24	Tierney, et al., Disorders of the Airways, Current Medical Diagnosis and Treatment, Chapter 9, pages 241-255, (1997).
	25	Renkema et al., "Effects of Long-term Treatment With Corticosteroids in COPD," Chest, Vol. 109, pages 1156-1162 (1996).
	26	Cochrane et al., "Bronchial asthma and the role of β_2 agonists", Respiratory Medicine", Vol. 91(5), pages 275-279 (1997).
	27	Wilcke et al., "The effect of inhaled glucocorticosteroids in emphysema due to α_1 -antitrypsin deficiency", Respiratory Medicine, Vol. 91, pages 275-279 (1997).
	28	Smeenk et al., "Opportunistic longinfecties bij patiënten met chronische obstructieve longziekte; een bijwerking van inhalatiecorticosteroïden?", <u>English translation included</u> , dated March 11, 2003.
	29	Wyser et al., "Neu Aspekte in der Behandlung des Asthma bronchiale und chronisch obstruktiver Lungenkrankheiten, Schweiz-Med Wochenschr, Vol. 127, pages 885-890 (1997), <u>English Summary included</u> .
	30	"Ventide Inhaler," ABPI Data Sheet Compendium, 1990-91 (3 pages).
	31	Barnes, "A New Approach to the Treatment of Asthma," Drug Therapy, Vol. 321(22), pages 1517-1527 (2002).
	32	"Foradil: Fast relief that lasts," Ciba-Geigy Limited, Switzerland, Medical and Pharmaceutical Information, Update 1994 (51 pages).
	33	English Translation of Opposition filed against Chilean Patent Application No. 2744-2001 (3 pages).
	34	Response to an Opposition in Chilean Application No. 2744/2001, dated August 6, 2006, <u>English Translation included</u> (6 pages).
	35	Request for Revocation of the Corresponding Patent in Turkey (TR 2000 00726), dated June 6, 2009 (15 pages).
	36	Notice of Opposition, filed by Ranbaxy Laboratories Limited, opposing the grant of Patent Application No. 190791 by Intellectual Property India (India Patent Office), dated June 1, 2006 (21 pages).
	37	Reply statement before the Opposition Board, Patent Office, Delhi, India; submitted on behalf of AstraZeneca, dated July 27, 2006 (6 pages).
	38	Affidavit of Jan William Trofast, before the Opposition Board, Patent Office, Delhi, India; submitted on behalf of AstraZeneca, dated September 13, 2006 (7 pages).
	39	Opponent Response in Opposition to Indian Patent No. 190791, submitted to Patent Office, Delhi, India, by Lakshmi Kumaran & Sridharan, dated November 3, 2006 (6 pages).

Examiner Signature /Jennifer Kim/	Date Considered 03/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 06275-0188001	Application No. 09/367,950
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Tommy Ekstrom	
		Filing Date August 18, 1999	Group Art Unit 1617

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	40	U.S. Examiner Jennifer M. Kim, Notice of Allowance in U.S. Serial No. 10/010,283, mailed August 28, 2009 (14 pages).
	41	Fish & Richardson P.C., Response to Final Office Action in U.S. Serial No.: 10/665,240, filed December 11, 2009 (12 pages).

Examiner Signature /Jennifer Kim/	Date Considered 03/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/